Bryce Istvan
Contributor since: 2011
Company: Oncoceutics
Sarepta Therapeutics: No Longer A Momentum Play, But Long-Term Value Remains
Today's NPS Deal- Putting Drugs In The Right Hands
Questcor Drops On Headline Misunderstanding
NPS Pharmaceuticals: Preparing For Tuesday's Advisory Committee Meeting
The Prostate Pipeline Revisited
The Rosetta Genomics Roller Coaster Ride
Nothing About Targacept's Fundamental Story Has Changed, But It Is 30% Cheaper
Shipping Is Weak But Dryships Is Still Cheap
Caradigm And The Future Of Healthcare IT
Merrimack IPO: Repackaging And Refining Chemotherapy
Amgen's Xgeva Prostate Indication Expansion Could Be Blockbuster On Its Own
Targacept: What's Left After Latest TC-5214 Disappointment?
A Rare Earth Metal Stock That Pays You To Wait
Life Science Venture Capital For Retail Investors
Dryships Is Still A Long-Term Buy
5 Drugs That Own The Prostate Pipeline
NPS Pharmaceuticals Gets Good News (Finally)
NPS Pharmaceuticals' Sell-Off Was Overdone
Power-One: Cyclically Weak, Fundamentally Sound
PMT: A Different Style mREIT Now At An Attractive Entry-Point
The DryShips Disconnect